Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).

Keytruda (pembrolizumab) - Merck (MSD)

NG-350A - Akamis Bio

https://meetings.asco.org/abstracts-presentations/226479

Minesh Patel; Chris Cox; David Krige; Lyle Walker; Vladimir Evilevitch; Jo Carter; Matthew Thomas; Samantha Bucktrout; Brian Champion; Thomas Lillie; Lee S. Rosen; Aung Naing

Apr 27, 2023